Welcome to our dedicated page for IBEX SEC filings (Ticker: IBEX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on IBEX's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into IBEX's regulatory disclosures and financial reporting.
IBEX Ltd Chief Executive Officer Robert Thomas Dechant reported selling a total of 12,000 Common Shares in two open-market transactions. He sold 6,000 shares on February 19, 2026 at a weighted average price of $29.7264 per share and another 6,000 shares on February 20, 2026 at a weighted average price of $29.3997 per share. After these sales, he continued to hold 281,406 Common Shares directly.
IBEX LTD reported insider sales via Rule 144 filings. The excerpt shows three reported dispositions of 6,000 common shares each by Robert Dechant c/o RBC Capital Markets LLC on 02/17/2026, 02/18/2026, and 02/19/2026, with gross proceeds of $177,786.00, $179,853.00, and $178,358.00 respectively.
IBEX Ltd director Keen Shuja filed an initial ownership report on Form 3. The filing shows indirect ownership of 16,480 Common Shares, held "by self as sole owner of Adia Global LLC." This is a disclosure of existing holdings rather than a new stock purchase or sale.
IBEX Ltd. filed a Form 144/A disclosing notice of proposed sale of 6,000 common shares. The filing lists recent sales by a reporting person, including Robert Dechant who sold 6,000 shares on 02/17/2026 for $177,786.00 and 6,000 shares on 02/18/2026 for $179,853.00.
Robert Dechant reported a proposed sale of 6,000 common shares of IBEX under a Rule 144 notice. The filing lists two prior sales in the past three months: 6,000 shares sold on 02/17/2026 for $1,777,786.00 and 6,000 shares sold on 02/18/2026 for $179,853.00.
IBEX Ltd Chief Executive Officer and director Robert Thomas Dechant reported open-market sales of company common shares on two consecutive days. He sold 6,000 common shares on February 17 at a weighted average price of $29.6310 per share and another 6,000 shares on February 18 at a weighted average price of $29.9756 per share.
Both transactions were executed as multiple trades within stated price ranges, with detailed trade-level information available on request. Following these sales, Dechant directly owns 293,406 IBEX common shares.
Ibex Ltd reported a Rule 144 notice for the sale of 6,000 common shares by a selling party represented by RBC Capital Markets. The filing lists the sale date as 02/17/2026 and an aggregate amount of $177,786.00. The shares trace to an RSA vest dated 12/28/2018.
Ibex had a shareholder file a notice to sell 6,000 shares of its common stock under Rule 144. The planned sale, with an aggregate market value of $177,786.00, is expected around 02/17/2026 through RBC Capital Markets LLC on Nasdaq.
The 6,000 shares were acquired on 12/28/2018 via an RSA vest from the issuer. Ibex had 13,405,520 shares of this class outstanding, providing context for the size of the proposed sale.
IBEX Ltd’s Chief Sales/Marketing Officer, Julie K. Casteel, reported equity compensation activity in company common shares. On February 6, 2026, she acquired 97,126 restricted shares at $0 per share through a grant tied to a performance share award based on revenue and EBITDA targets.
On the same date, 8,649 shares were disposed of at $34.98 per share, representing shares withheld to cover taxes upon vesting. After these transactions, she directly held 116,794 common shares. One-third of the performance-based shares vested on February 6, 2026, with additional one-third tranches scheduled to vest on February 6, 2027 and February 6, 2028, subject to her continued service.
IBEX Ltd’s Chief Legal Officer, Christina Alice Trofimuk-O'Connor, reported equity compensation activity. On February 6, 2026, she acquired 19,557 common shares at $0 as a restricted stock award tied to an April 20, 2022 performance share grant based on revenue and EBITDA targets.
On the same date, 2,176 common shares were disposed of at $34.98 to cover taxes due at vesting. After these transactions, she directly held 31,335 IBEX common shares. One-third of the award vested on February 6, 2026, with additional thirds scheduled to vest on February 6, 2027 and February 6, 2028, subject to her continued service.